880.1500 -23.10 (-2.56%)
NSE Jan 09, 2026 15:31 PM
Volume: 83,200
 

880.15
-2.56%
AUM Capital
Glenmark Life Sciences (GLS) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells Active Pharmaceutical Ingridients (APIs) for gastro-intestinal disorders, antiinfectives and other therapeutic areas. As of March 2021, GLS had a portfolio of 120 molecules globally and sold APIs in India and exported APIs to multiple countries in Europe, North America, Latin America,...
Number of MF schemes decreased from 18 to 11 in Sep 2025 qtr
More from Alivus Life Sciences Ltd.
Recommended